# Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function

> **NCT06145282** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 6 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **BIOLOGICAL:** Briquilimab
- **DRUG:** Filgrastim
- **DRUG:** Abatacept
- **DRUG:** Sirolimus
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT06145282
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-28
- **Primary completion:** 2025-10-27
- **Final completion:** 2027-11-26
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06145282

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06145282, "Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06145282. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*